Overview of Postmarketing Drug Safety Reporting Requirements - REdI 2020
Postmarketing Safety and Surveillance of Generic Drugs Update
Postmarketing Drug Safety Compliance: 2019 Inspection Findings
Postmarketing Adverse Drug Experience (PADE) Inspections – (1of3) Jun. 19, 2018
Good Clinical Practice & Pharmacovigilance Compliance Symposium | D3S06 - (PV): Regulatory Updates
Investigational New Drug Safety Reporting Requirements (10of14) REdI 2018
MDUFA IV: Accessing and Using Real-World and Postmarket Data for Regulatory Decision-Making
Combination Products: Reporting Device Information and Malfunctions - Pharmacovigilance 2020
Introduction to Drug Safety
Post-Marketing Drug Safety Surveillance with Dr. Peter Waldron
EU Pharmacovigilance and Drug Safety Regulations and Compliance
Postmarket Safety Surveillance: Tools, Methods, and Benefit-Risk Framework - Pharmacovigilance 2020
How the FDA can make better decisions on drug safety
FDA Adverse Event Reporting System (FAERS) Overview - Pharmacovigilance 2020
Webinar: Pharmacovigilance Advanced Learning - Aggregate Reports Guidance
Drug Safety and Pharmacovigilance Trailer
BIMO, REMS, and PADE Inspection Readiness (3of3) Jun. 19, 2018
The Importance of Generic Drug Pharmacovigilance (9of16) Generic Drugs Forum 2020
Postmarketing Safety Management
